<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569748</url>
  </required_header>
  <id_info>
    <org_study_id>215/2017/PO</org_study_id>
    <nct_id>NCT03569748</nct_id>
  </id_info>
  <brief_title>Heated Tobacco Products vs Electronic Cigarettes</brief_title>
  <official_title>Randomized, Non-Inferiority Trial ComparingCigarette Consumption, Adoption Rates, Acceptability, Tolerability, and Tobacco Harm Reduction Potential in Smokers Switching to Heated Tobacco Products or Electronic Cigarettes: Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Catania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-weeks, open label, non-inferiority trial comparing HTPs vs ECs in terms of&#xD;
      efficacy, adoption rate and acceptability, tolerability, and tobacco harm reduction in 220&#xD;
      healthy smokers, not motivated to quit, randomized (1:1) to switch to one of these products.&#xD;
      The duration of the study, from the enrollment to the study close out for all the patients at&#xD;
      week 24 (follow-up), will be approximately 12 months. Enrollment period will last about 6&#xD;
      months with the support of a multi-channel advertising method. This will include&#xD;
      location-based advertising on social networks, advertising in local media, information days&#xD;
      organized within the city.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the baseline visit, a face to face screening (V0) for pre-eligibility checks will be&#xD;
      conducted. Subjects will be asked to practice with the step test for 10-15 minand will be&#xD;
      instructed how to collect and store their morning urine before bringing it to the hospital on&#xD;
      their Baseline visit (V1). This study will consist of a baseline visit (V1) and 6 follow-up&#xD;
      study visits (V2-V7). At baseline (V1), participants will be randomized in two separate study&#xD;
      groups. The randomization sequence will be computer generated by using blocks size of 5, with&#xD;
      an allocation ratio of 1:1 for each of the study products (IQOS, JustFog-EC). Subjects will&#xD;
      use and familiarize with their allocated product, as per randomization. They will be trained&#xD;
      and counseled on the use of their allocated study product; oral explanation and practical&#xD;
      demonstration will be followed by product trial during which participants will also have the&#xD;
      option to try and choose their preferred flavour (either from a selection of 3 e-liquids or 3&#xD;
      tobacco sticks, depending on the allocated arm). Participants randomized in the IQOS arm will&#xD;
      receive one iQOS kit and a full 1 week supply of tobacco sticks of their choice (they will&#xD;
      receive a number of tobacco sticks/day corresponding to the number of cigarettes smoked at&#xD;
      baseline); those randomized in the JustFog-EC arm of the study will receive one JustFog&#xD;
      Starter Kit and a full 1 week supply of e-liquids of their choice (they will receive 4, 10&#xD;
      mls refill containers).Free products will be supplied at each subsequent visit throughout the&#xD;
      study. No supply of tobacco stick or e-liquid will be given at week-12, but users will be&#xD;
      offered to keep using their products to minimize the risk of relapsing back to cigarette&#xD;
      smoking. A prospective evaluation of cigarette consumption, adoption rates, acceptability and&#xD;
      tolerability will be recorded throughout the study.&#xD;
&#xD;
      Visit 2 (V2):This will be scheduled 1 week after V1 (with a tolerance of +/- 3 days).&#xD;
      Cigarette/day, eCO, AEs, BP, HR will be measured and product use recorded. Full 1 week supply&#xD;
      of the chosen product will be provided.&#xD;
&#xD;
      Visit 3 (V3):This will be scheduled 2 weeks after V1 (with a tolerance of +/- 3 days).&#xD;
      Cigarette/day, eCO, AEs, BP, HR will be measured and product use recorded. Participants will&#xD;
      be instructed on how to collect and store their second urine sample before bringing it to the&#xD;
      hospital at V4. Full 2 weeks supply of the chosen product will be provided.&#xD;
&#xD;
      Visit 4 (V4):This will be scheduled 4 weeks after V1 (with a tolerance of +/- 3 days).&#xD;
      Cigarette/day, eCO, AEs, BP, HR will be measured, questionnaires completed and product use&#xD;
      recorded. Step test will be carried out. Second urine sample will be collected, aliquotted&#xD;
      and stored. Full 4 weeks supply of the chosen product will be provided.&#xD;
&#xD;
      Visit 5 (V5):This will be scheduled 8 weeks after V1 (with a tolerance of +/- 7 days).&#xD;
      Cigarette/day, eCO, AEs, BP, HR will be measured, questionnaires completed and product use&#xD;
      recorded. Full 4 weeks supply of the chosen product will be provided.&#xD;
&#xD;
      Visit 6 (V6):This will be scheduled 12 weeks after V1 (with a tolerance of +/- 7 days).&#xD;
      Cigarette/day, eCO, AEs, BP, HR, weight, height will be measured, questionnaires completed&#xD;
      and product use recorded. Step test will be carried out. No more products will be dispensed.&#xD;
&#xD;
      Follow-up Visit (V7):This final visit will be scheduled 24 weeks after V1 (with a tolerance&#xD;
      of +/- 7 days)to review product usage and smoking behavior under naturalistic condition of&#xD;
      use. Cigarette/day, eCO, AEs, BP, HR, weight, height will be measured, questionnaires&#xD;
      completed and product use recorded. Step test will be carried out.&#xD;
&#xD;
      Data will be recorded from every subject on an electronic CRF, provided by a CRO, GCP&#xD;
      compliant, 21 CFR Part 11 FDA compliant, listed in AIFA list of operating CRO. Urine samples&#xD;
      will be collected at baseline and wk 4, and sent to an external laboratory for analytical&#xD;
      assessment of selected Biomarkers of Exposure (BoE).&#xD;
&#xD;
      The study will be conducted at the University of Catania, Catania, Italy.&#xD;
&#xD;
      Participants Healthy smokers, not motivated to quit, will be randomized in two intervention&#xD;
      groups in a 1:1 ratio to compare HTPs vs ECs in terms of reductions in cigarette consumption,&#xD;
      adoption rate and acceptability, tolerability, and tobacco harm reduction. Sample size&#xD;
      determination (better detailed below, in the relevant section) for no-inferiority testing is&#xD;
      based on the assumptions that 1) expected quit rates based on most recent EC literature is&#xD;
      about 20-25% and 2) that differences in quit rates between products under investigation&#xD;
      should not exceed 10-15% (as per non-inferiority definition). According to these hypotheses&#xD;
      the required number of participants per study arm is 104. Hence investigators intend to&#xD;
      include 220 participants, 110 per group.&#xD;
&#xD;
      Study Products Tested&#xD;
&#xD;
        -  Heated Tobacco Product (HTP):Investigators will use a HTP that does not involve&#xD;
           combustion, generating a nicotine-containing aerosol. At the time of writing, IQOS is&#xD;
           the only HTP available on the Italian market. IQOS is composed by: 1) a tobacco stick -&#xD;
           a novel patent-pending tobacco product with unique processed tobacco made from tobacco&#xD;
           powder; 2) an electronic holder into which the tobacco stick is inserted and which heats&#xD;
           the tobacco by means of an electronically controlled heating blade; 3) a charger that is&#xD;
           used to recharge the holder after each use.&#xD;
&#xD;
        -  Investigators will use the three types of tobacco sticks specifically designed for&#xD;
           IQOS(named HEETS) that are currently for sale in the Italian market: Heets Amber, Heets&#xD;
           Yellow, and Heets Turquoise. These products are compliant to the EU Tobacco Product&#xD;
           Directive.&#xD;
&#xD;
        -  Electronic Cigarette (EC):JustFog Q16 Starter Kit and three types of e-liquid flavours,&#xD;
           Puff Riserva Country 16 mg, Puff Riserva Toscana 16 mg, and Puff Artic 16 mg (2&#xD;
           tobacco-flavours and one menthol flavour), were chosen for the study.&#xD;
&#xD;
        -  Products were selected by an Italian expert panel of 3 e-liquid producers and 3 vaping&#xD;
           product distributors, moderated by the editor of a popular e-cigarette blog. Experts&#xD;
           convened in Verona (Italy) during a major vaping expo event. Through consensus, the&#xD;
           expert panel provided specific recommendation on the device(JustFog Q16 Starter Kit is&#xD;
           one of the most popular e-cigarette device in Italy due to its good performance and&#xD;
           quality, affordable price, and user friendliness especially for beginners) and the&#xD;
           choice of e-liquids that could best match the sensorial experience of the iQOS tobacco&#xD;
           sticks to be used in a switching study and minimize the local irritant effects of&#xD;
           excessive PG/VG ratio. These products are compliant to the EU Tobacco Product Directive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2019</start_date>
  <completion_date type="Actual">May 25, 2020</completion_date>
  <primary_completion_date type="Actual">May 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Smoking Cessation</measure>
    <time_frame>12 WEEK</time_frame>
    <description>to compare the efficacy of HTP and EC, in terms of quit rates at week 12, by self-reporting abstinence from classic cigarette [validated by an Exhaled breath Carbon monoxide (eCO) measurement ≤10ppm)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Smoking Reduction</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the smoking reduction derived from the use of HTP and EC, intended as a 50% reduction in the number of conventional cigarette/day at week 12, defined through self-reporting;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adoption Rate</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the adoption rate to product use [by collecting (empty) refill bottles and used heathsticks on a daily basis, verified by a study diary filled daily by the subject];</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare the acceptability derived from the use of HTP and EC by the modified Cigarette Evaluation Questionnaire (mCEQ). It is a self-administered questionnaire that contains 12 items covering both reinforcing and aversive effects of smoking. The items are rated on a 7-point scale from 1 not at all to 7 extremely&#xD;
The total mCEQ score range from min 12 to max 84. Higher scores for the total mCEQ reflect a better outcome. There are also the following 5 subscales:&#xD;
Smoking Satisfaction (items 1, 2, 12) range of scores min 3 max 21;higher scores mean a better outcome.&#xD;
Psychological Reward (items 4-8), range of scores min 5 max 35; higher scores mean a better outcome.&#xD;
Aversion (items 9 and 10), range of scores min 2 max 14;higher scores mean a worse outcome.&#xD;
Single item score Enjoyment Respiratory Tract Sensations (item 3) range scores min 1 max 7;higher scores mean a better outcome.&#xD;
Single item score Craving Reduction (item 11), higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Product-related Adverse Events</measure>
    <time_frame>Week 12</time_frame>
    <description>To compare number of participants with adverse events derived from the use of HTP and EC as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Biomarkers of Biological Effects (BoBE)</measure>
    <time_frame>Week 12</time_frame>
    <description>changes in Biomarkers of Biological Effects (BoBE) such as: eCO in the exhaled breath (i.e. eCO), step test values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliability</measure>
    <time_frame>Baseline visit, Week 12</time_frame>
    <description>To compare the reliability of HTP and EC, in terms of incidence and kind of malfunctioning events, through self-reporting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Smoking, Cigarette</condition>
  <arm_group>
    <arm_group_label>IQOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HEAT NOT BURN REDUCED RISK PRODUCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-CIG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ELECTRONIC CIGARETTE REDUCED RISK PRODUCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IQOS</intervention_name>
    <description>IQOS USE FOR 12 WEEKS</description>
    <arm_group_label>IQOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>E-CIG</intervention_name>
    <description>ELECTRONIC CIGARETTE FOR 12 WEEKS</description>
    <arm_group_label>E-CIG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for enrolment&#xD;
        into the study:&#xD;
&#xD;
          1. Able to comply with the study procedures&#xD;
&#xD;
          2. Male or female healthy smokers aged ≥19&#xD;
&#xD;
          3. Smoking at least 10 cigarettes a day&#xD;
&#xD;
          4. Smoking for at least one year&#xD;
&#xD;
          5. Not currently attempting to quit smoking or wishing to do so in the next 30 days (this&#xD;
             will be verified at screening by the answer ''NO'' to both questions ''Do you intend&#xD;
             to quit in the next 30 days?'' and ''Are you interested in taking part in one of our&#xD;
             smoking cessation programs?'')&#xD;
&#xD;
          6. Female smokers not planning to become pregnant are using an acceptable form of&#xD;
             contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a subject from study enrolment:&#xD;
&#xD;
          1. Use of smokeless tobacco, or any other tobacco products (including e-cigarettes,&#xD;
             cigars, chewing tobacco, snus, etc.) within the last 3 months, at baseline and during&#xD;
             the whole study.&#xD;
&#xD;
          2. Use of nicotine replacement therapy or other smoking cessation therapies within the&#xD;
             last 3 months and at baseline.&#xD;
&#xD;
          3. Self-reported pregnancy, planned pregnancy or breastfeeding.&#xD;
&#xD;
          4. Tobacco industry employees and 1st degree relatives will be excluded in order to&#xD;
             safeguard independence of the study&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Catania, Italy</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <results_first_submitted>November 27, 2020</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Catania</investigator_affiliation>
    <investigator_full_name>Enrico Gian Maria Mondati</investigator_full_name>
    <investigator_title>Researcher of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>harm reduction</keyword>
  <keyword>electronic cigarette</keyword>
  <keyword>heated tobacco product</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03569748/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03569748/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IQOS</title>
          <description>HEAT NOT BURN REDUCED RISK PRODUCT&#xD;
IQOS: IQOS USE FOR 12 WEEKS</description>
        </group>
        <group group_id="P2">
          <title>E-CIG</title>
          <description>ELECTRONIC CIGARETTE REDUCED RISK PRODUCT&#xD;
E-CIG: ELECTRONIC CIGARETTE FOR 12 WEEKS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IQOS</title>
          <description>HEAT NOT BURN REDUCED RISK PRODUCT&#xD;
IQOS: IQOS USE FOR 12 WEEKS</description>
        </group>
        <group group_id="B2">
          <title>E-CIG</title>
          <description>ELECTRONIC CIGARETTE REDUCED RISK PRODUCT&#xD;
E-CIG: ELECTRONIC CIGARETTE FOR 12 WEEKS</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="16.1"/>
                    <measurement group_id="B2" value="41.3" spread="16.9"/>
                    <measurement group_id="B3" value="41.3" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Smoking Cessation</title>
        <description>to compare the efficacy of HTP and EC, in terms of quit rates at week 12, by self-reporting abstinence from classic cigarette [validated by an Exhaled breath Carbon monoxide (eCO) measurement ≤10ppm)]</description>
        <time_frame>12 WEEK</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQOS</title>
            <description>HEAT NOT BURN REDUCED RISK PRODUCT&#xD;
IQOS: IQOS USE FOR 12 WEEKS</description>
          </group>
          <group group_id="O2">
            <title>E-CIG</title>
            <description>ELECTRONIC CIGARETTE REDUCED RISK PRODUCT&#xD;
E-CIG: ELECTRONIC CIGARETTE FOR 12 WEEKS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Smoking Cessation</title>
          <description>to compare the efficacy of HTP and EC, in terms of quit rates at week 12, by self-reporting abstinence from classic cigarette [validated by an Exhaled breath Carbon monoxide (eCO) measurement ≤10ppm)]</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: P1-P2 ≤ -Margin</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Margin=0.04</non_inferiority_desc>
            <p_value>0.0051</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Proportion Difference</param_type>
            <param_value>0.1342</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0014</ci_lower_limit>
            <ci_upper_limit>0.2671</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Smoking Reduction</title>
        <description>To compare the smoking reduction derived from the use of HTP and EC, intended as a 50% reduction in the number of conventional cigarette/day at week 12, defined through self-reporting;</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQOS</title>
            <description>HEAT NOT BURN REDUCED RISK PRODUCT&#xD;
IQOS: IQOS USE FOR 12 WEEKS</description>
          </group>
          <group group_id="O2">
            <title>E-CIG</title>
            <description>ELECTRONIC CIGARETTE REDUCED RISK PRODUCT&#xD;
E-CIG: ELECTRONIC CIGARETTE FOR 12 WEEKS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Smoking Reduction</title>
          <description>To compare the smoking reduction derived from the use of HTP and EC, intended as a 50% reduction in the number of conventional cigarette/day at week 12, defined through self-reporting;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adoption Rate</title>
        <description>To compare the adoption rate to product use [by collecting (empty) refill bottles and used heathsticks on a daily basis, verified by a study diary filled daily by the subject];</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQOS</title>
            <description>4 PARTICIPANTS WITHOUT ADHERENCE IN IQOS GROUP</description>
          </group>
          <group group_id="O2">
            <title>E-CIG</title>
            <description>19 PARTICIPANTS WITHOUT ADHERENCE IN E-CIG GROUP</description>
          </group>
        </group_list>
        <measure>
          <title>Adoption Rate</title>
          <description>To compare the adoption rate to product use [by collecting (empty) refill bottles and used heathsticks on a daily basis, verified by a study diary filled daily by the subject];</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Percentage Difference</param_type>
            <param_value>14.2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acceptability</title>
        <description>To compare the acceptability derived from the use of HTP and EC by the modified Cigarette Evaluation Questionnaire (mCEQ). It is a self-administered questionnaire that contains 12 items covering both reinforcing and aversive effects of smoking. The items are rated on a 7-point scale from 1 not at all to 7 extremely&#xD;
The total mCEQ score range from min 12 to max 84. Higher scores for the total mCEQ reflect a better outcome. There are also the following 5 subscales:&#xD;
Smoking Satisfaction (items 1, 2, 12) range of scores min 3 max 21;higher scores mean a better outcome.&#xD;
Psychological Reward (items 4-8), range of scores min 5 max 35; higher scores mean a better outcome.&#xD;
Aversion (items 9 and 10), range of scores min 2 max 14;higher scores mean a worse outcome.&#xD;
Single item score Enjoyment Respiratory Tract Sensations (item 3) range scores min 1 max 7;higher scores mean a better outcome.&#xD;
Single item score Craving Reduction (item 11), higher scores mean a better outcome</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQOS</title>
            <description>MEAN CHANGES AT FINAL VISIT (WEEK 12) FROM BASELINE IN MCEQ SCORES: O.73</description>
          </group>
          <group group_id="O2">
            <title>E-CIG</title>
            <description>MEAN CHANGES AT FINAL VISIT (WEEK 12) FROM BASELINE IN MCEQ SCORES: -O.17</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability</title>
          <description>To compare the acceptability derived from the use of HTP and EC by the modified Cigarette Evaluation Questionnaire (mCEQ). It is a self-administered questionnaire that contains 12 items covering both reinforcing and aversive effects of smoking. The items are rated on a 7-point scale from 1 not at all to 7 extremely&#xD;
The total mCEQ score range from min 12 to max 84. Higher scores for the total mCEQ reflect a better outcome. There are also the following 5 subscales:&#xD;
Smoking Satisfaction (items 1, 2, 12) range of scores min 3 max 21;higher scores mean a better outcome.&#xD;
Psychological Reward (items 4-8), range of scores min 5 max 35; higher scores mean a better outcome.&#xD;
Aversion (items 9 and 10), range of scores min 2 max 14;higher scores mean a worse outcome.&#xD;
Single item score Enjoyment Respiratory Tract Sensations (item 3) range scores min 1 max 7;higher scores mean a better outcome.&#xD;
Single item score Craving Reduction (item 11), higher scores mean a better outcome</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="-1.04" upper_limit="2.49"/>
                    <measurement group_id="O2" value="-0.17" lower_limit="-1.77" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Product-related Adverse Events</title>
        <description>To compare number of participants with adverse events derived from the use of HTP and EC as assessed by CTCAE v4.0</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQOS</title>
            <description>HEAT NOT BURN REDUCED RISK PRODUCT&#xD;
IQOS: IQOS USE FOR 12 WEEKS</description>
          </group>
          <group group_id="O2">
            <title>E-CIG</title>
            <description>ELECTRONIC CIGARETTE REDUCED RISK PRODUCT&#xD;
E-CIG: ELECTRONIC CIGARETTE FOR 12 WEEKS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Product-related Adverse Events</title>
          <description>To compare number of participants with adverse events derived from the use of HTP and EC as assessed by CTCAE v4.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Biomarkers of Biological Effects (BoBE)</title>
        <description>changes in Biomarkers of Biological Effects (BoBE) such as: eCO in the exhaled breath (i.e. eCO), step test values</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IQOS</title>
            <description>at v6 (week 12) mean(sd) eCO: 8.2 (8.0)&#xD;
at v6 (week 12) mean(sd) Step Test VoMax: 44.7 (28.7)</description>
          </group>
          <group group_id="O2">
            <title>E-CIG</title>
            <description>at v6 (week 12) mean(sd) eCO: 10.1 (11.3)&#xD;
at v6 (week 12) mean(sd) Step Test VoMax: 50.9 (31.9)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Biomarkers of Biological Effects (BoBE)</title>
          <description>changes in Biomarkers of Biological Effects (BoBE) such as: eCO in the exhaled breath (i.e. eCO), step test values</description>
          <units>ppm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="8.0"/>
                    <measurement group_id="O2" value="10.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reliability</title>
        <description>To compare the reliability of HTP and EC, in terms of incidence and kind of malfunctioning events, through self-reporting.</description>
        <time_frame>Baseline visit, Week 12</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Any participants showed/reported signs and symptoms considered serious by the medical investigators with absence of all-cause of mortality</desc>
      <group_list>
        <group group_id="E1">
          <title>IQOS</title>
          <description>HEAT NOT BURN REDUCED RISK PRODUCT&#xD;
IQOS: IQOS USE FOR 12 WEEKS</description>
        </group>
        <group group_id="E2">
          <title>E-CIG</title>
          <description>ELECTRONIC CIGARETTE REDUCED RISK PRODUCT&#xD;
E-CIG: ELECTRONIC CIGARETTE FOR 12 WEEKS</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="110"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="110"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Signorelli</name_or_title>
      <organization>University of Catania</organization>
      <phone>095.378.2636/794</phone>
      <email>maria.signorelli@unict.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

